Search

Up to 20 percent of people over the age of 70 have clonal hematopoiesis of indeterminate potential (CHIP), a condition that carries twice the risk of coronary heart disease and ischemic stroke, and worse outcomes after heart failure — independent of traditional cardiovascular risk factors.

… Tuesday, October 8, 2019 Up to 20 percent of people over the age of 70 have clonal hematopoiesis of indeterminate potential (CHIP), a condition that carries twice the risk of coronary heart disease and ischemic stroke, and worse outcomes after heart failure — independent of traditional cardiovascular

在 70 岁以上的人群中，高达 20% 的人有不确定潜能的克隆性造血 (CHIP)，这种情况会带来双倍冠心病和缺血性中风风险，并且导致心力衰竭后预后更差 — 无论传统的心血管风险因素如何。

… Tuesday, October 8, 2019 在 70 岁以上的人群中，高达 20% 的人有不确定潜能的克隆性造血 (CHIP)，这种情况会带来双倍冠心病和缺血性中风风险，并且导致心力衰竭后预后更差 — 无论传统的心血管风险因素如何。 该状况包括由造血干细胞中的体细胞突变引起的外周血突变白细胞。随着人口老龄化的增长，越来越多 CHIP 患者将前往心血管医生处就诊。 就使用 CHIP 筛查、评估和管理患者的最佳方法，仍存在一些疑问。我们和其他癌症研究中心的同事们一起，最近在 《美国心脏病学会杂志》 上发表了一篇论文。我们在论文中对 CHIP 进行了说明，回顾了一些临床问题，为 CHIP 患者的心血管风险管理提供了一些合理化建议

Help save lives. Get immunized.

… Friday, December 18, 2020 Memorial Sloan Kettering (MSK) Healthcare Heroes are rolling up their sleeves to receive the COVID-19 vaccine. COVID-19 vaccination is our best shot at controlling/ ending this global pandemic and helping protect our immunocompromised patients, their families, MSK staff, and

Researchers at the Sloan Kettering Institute have found that gut microbes shape the immune system of mice in an unexpected way.

… Wednesday, May 12, 2021 The immune system’s main job is identifying things that can make us sick. In the language of immunology, this means distinguishing “self” from “non-self”: The cells of our organs are self, while disease-causing bacteria and viruses are non-self. But what about the billions of

Read about a new treatment combining bispecific antibodies that is effective against extramedullary myeloma.

… Sunday, December 7, 2025 Researchers have made  great progress in the treatment of  multiple myeloma , a rare blood cancer, over the past decade. One important advance has been the emergence of a new class of drugs called bispecific antibodies, which work well in people for whom previous treatments have

During World War II, US factories famously converted their operations to support the war effort. COVID-19 instigated something similar among cancer scientists.

… Friday, January 8, 2021 Summary When COVID-19 hit, cancer researchers at MSK used their expertise in genomics to help solve the mystery of how the virus infects human cells. “I remember thinking I wanted to do something,” recalls Francisco J. Sánchez-Rivera , a postdoctoral fellow in Scott Lowe’s lab

A number of Gerstner Sloan Kettering students working in labs across MSK have received prestigious fellowships granted by external agencies and benefactors of the school.

… Friday, August 29, 2025 This past year, seven PhD students enrolled in the  Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) were awarded competitive fellowships from prestigious external agencies such as the National Institutes of Health (NIH) and the National Science Foundation

Memorial Sloan Kettering Cancer Center and MediSys Health Network today announced a new collaboration that will expand access to world-class cancer care for the people of Queens and eastern Brooklyn.

… Thursday, January 12, 2023 Memorial Sloan Kettering Cancer Center (MSK) and MediSys Health Network (Jamaica Hospital Medical Center and Flushing Hospital Medical Center) today announced a new collaboration that will expand access to world-class cancer care for the people of Queens and eastern Brooklyn

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

… Wednesday, May 18, 2022 New findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) and published today in the journal Nature Communications report the results of using a comprehensive sequencing approach on 114 pediatric, adolescent, and young adult patients with solid tumors. The

Naxitamab was created at MSK and has received Breakthrough Therapy Designation from the FDA.

… Friday, September 28, 2018 Summary Naxitamab was created at MSK and has received Breakthrough Therapy Designation from the FDA for the treatment of patients with high-risk neuroblastoma. Neuroblastoma is a rare cancer of the nerve tissue that usually arises in the abdomen. It mainly affects young children